Pharmafile Logo
Pharmafocus logo
Advanced Search

Krystexxa

Showing 1 posts of 1 posts found.

Savient plays down gout drug manufacturing problems

January 11, 2011
Manufacturing and Production, Sales and Marketing Krystexxa, Savient, biologic manufacturing, gout, manufacturing compliance, pegloticase

Savient Pharmaceuticals has reported that some production batches of Krystexxa, its recently-approved second-line treatment for gout, have failed to meet …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025